DehydraTECH-liraglutide
/ Lexaria Biosci
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
February 05, 2026
Lexaria Announces Positive Final Results From Human Pilot Study #5Lexaria Announces Positive Final Results From Human Pilot Study #5
(Nasdaq)
- "'In addition to achieving the Study's primary safety and tolerability endpoint, we also demonstrated that oral DehydraTECH-liraglutide functioned comparably to traditionally injected liraglutide, consistent with our regulatory development pathway objectives.'....In light of this issue, the PK testing from the Study was limited to exploratory visualization of the raw ELISA signals which, nonetheless, over time demonstrated broadly similar temporal patterns between the DHT-LIR and the SAX-LIR. The visualization of the similar signal patterns of the two treatments is consistent with the instances of functional comparability otherwise demonstrated in the Study, pursuant to Lexaria's regulatory development pathway objectives."
Clinical data • Obesity
February 20, 2025
Lexaria's Strategic Business Pursuit of DehydraTECH-Liraglutide
(ACCESSWIRE)
- "Lexaria Bioscience...announces that it has made a strategic business decision to further investigate the commercial opportunities and applications for a unique new GLP-1 solution: orally taken liraglutide processed with our wholly-owned DehydraTECH enhancement technology...As part of that strategic business decision, Lexaria has already filed certain patent applications related to DehydraTECH-enhanced oral liraglutide which, if granted, will further support Lexaria's ability to commercialize oral DehydraTECH-liraglutide...To support the broader strategy of entering the GLP-1 weight loss and diabetes control market as quickly as possible, Lexaria is also preparing to commence pilot clinical testing of DehydraTECH-liraglutide in humans, as announced on January 15, 2025, when we received the necessary independent ethics board approval that allowed our contract research organization to begin to implement and execute human pilot study GLP-1-H25-5 (the 'Study')."
Commercial • New trial • Diabetes • Obesity
1 to 2
Of
2
Go to page
1